

Jan Scicinski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2904440/publications.pdf>

Version: 2024-02-01

55
papers

1,717
citations

304602

22
h-index

289141

40
g-index

57
all docs

57
docs citations

57
times ranked

1954
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer and Beyond: Discovery and Development of NO-Releasing Therapeutics. , 2019, , 123-158.		1
2	The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. <i>Clinical Epigenetics</i> , 2017, 9, 4.	1.8	33
3	RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 109-119.	1.9	45
4	No patient left behind: The promise of immune priming with epigenetic agents. <i>Oncolmmunology</i> , 2017, 6, e1315486.	2.1	11
5	RRx-001 Reset: Chemoresensitization via NO-Mediated M1 Macrophage Repolarization. , 2017, , 35-56.		1
6	Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. <i>Oncotarget</i> , 2017, 8, 102511-102520.	0.8	10
7	Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. <i>Case Reports in Oncology</i> , 2016, 9, 285-289.	0.3	12
8	Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents. <i>Biomolecules</i> , 2016, 6, 32.	1.8	9
9	Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. <i>Medical Oncology</i> , 2016, 33, 85.	1.2	11
10	Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial. <i>Translational Oncology</i> , 2016, 9, 108-113.	1.7	28
11	Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. <i>Respiratory Medicine Case Reports</i> , 2016, 18, 62-65.	0.2	10
12	A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?. <i>Medical Oncology</i> , 2016, 33, 63.	1.2	15
13	Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. <i>Case Reports in Oncology</i> , 2016, 9, 164-170.	0.3	15
14	A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, CMO.S40429.	0.6	12
15	RRx-001, A novel dinitroazetidide radiosensitizer. <i>Investigational New Drugs</i> , 2016, 34, 371-377.	1.2	37
16	RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. <i>Clinical Epigenetics</i> , 2016, 8, 53.	1.8	20
17	Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy. <i>Oncotarget</i> , 2016, 7, 9041-9045.	0.8	5
18	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. <i>Oncotarget</i> , 2016, 7, 40781-40791.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. <i>Case Reports in Oncology</i> , 2015, 8, 461-465.	0.3	13
20	Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Manâ€”PFS2: A Measure of Therapeutic Action-At-A-Distance. <i>Neoplasia</i> , 2015, 17, 716-722.	2.3	21
21	From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. <i>Malaria Journal</i> , 2015, 14, 218.	0.8	15
22	Going viral: a review of replication-selective oncolytic adenoviruses. <i>Oncotarget</i> , 2015, 6, 19976-19989.	0.8	110
23	The War on Cancer: A Military Perspective. <i>Frontiers in Oncology</i> , 2015, 4, 387.	1.3	15
24	NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. <i>Redox Biology</i> , 2015, 6, 1-8.	3.9	98
25	Impact of hemoglobin nitrite to nitric oxide reductase on blood transfusion for resuscitation from hemorrhagic shock. <i>Asian Journal of Transfusion Science</i> , 2015, 9, 55.	0.1	15
26	Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1133-1142.	5.1	76
27	Discovery and Development of RRx-001, a Novel Nitric Oxide and ROS Mediated Epigenetic Modulator. , 2015, , 259-277.		2
28	Targeting Hyponitroxia in Cancer Therapy. , 2015, , 39-48.		2
29	Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001. <i>Oncotarget</i> , 2015, 6, 21547-21556.	0.8	34
30	Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. <i>Oncotarget</i> , 2015, 6, 43172-43181.	0.8	43
31	Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 1121-1127.	0.9	39
32	Follow the ATP: Tumor Energy Production: A Perspective. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 1187-1198.	0.9	64
33	Rewriting the Epigenetic Code for Tumor Resensitization: A Review. <i>Translational Oncology</i> , 2014, 7, 626-631.	1.7	37
34	Novel nitric oxide generating compound glycidyl nitrate enhances the therapeutic efficacy of chemotherapy and radiotherapy. <i>Biochemical and Biophysical Research Communications</i> , 2014, 447, 537-542.	1.0	35
35	Development of methods for the bioanalysis of RRx-001 and metabolites. <i>Bioanalysis</i> , 2014, 6, 947-956.	0.6	17
36	The Implications of Hyponitroxia in Cancer. <i>Translational Oncology</i> , 2014, 7, 167-173.	1.7	25

#	ARTICLE	IF	CITATIONS
37	Abstract 1420: RRx-001 inhibits glucose erythrocyte and tumor glucose 6-phosphate dehydrogenase. <i>Cancer Research</i> , 2014, 74, 1420-1420.	0.4	5
38	Abstract 2068: RRx-001 oxidation of redox sensitive protein thiols in tumors measured by Gd-LC7-SH enhanced MRI In preclinical tumor models. <i>Cancer Research</i> , 2014, 74, 2068-2068.	0.4	3
39	Abstract 906: Molecular imaging of RRx-001-induced oxidative stress in Nrf2-luciferase expressing SCC VII tumors in mice. , 2014, , .		2
40	A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2578-2578.	0.8	4
41	The Capacity of Red Blood Cells to Reduce Nitrite Determines Nitric Oxide Generation under Hypoxic Conditions. <i>PLoS ONE</i> , 2014, 9, e101626.	1.1	28
42	Real Time Dynamic Imaging and Current Targeted Therapies in the War on Cancer: A New Paradigm. <i>Theranostics</i> , 2013, 3, 437-447.	4.6	18
43	Abstract LB-86: Preliminary results from an ongoing phase I trial of RRx-001, a tumor selective cytotoxic agent.. , 2013, , .		1
44	Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1810-1816.	1.7	44
45	Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials. <i>Cancer Research</i> , 2012, 72, 2600-2608.	0.4	90
46	Oral Coadministration of Î²-Glucuronidase to Increase Exposure of Extensively Glucuronidated Drugs that Undergo Enterohepatic Recirculation. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 2545-2556.	1.6	8
47	Abstract 4371: RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors. <i>Cancer Research</i> , 2012, 72, 4371-4371.	0.4	10
48	Six Degrees of Separation: The Oxygen Effect in the Development of Radiosensitizers. <i>Translational Oncology</i> , 2011, 4, 189-198.	1.7	76
49	Abstract 676: Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. <i>Cancer Research</i> , 2011, 71, 676-676.	0.4	2
50	NO or No NO, Increased Reduction of Nitrite to Nitric Oxide by Modified Red Blood Cells. <i>Blood</i> , 2011, 118, 2125-2125.	0.6	11
51	Microwave-assisted saccharide coupling with n-pentenyl glycosyl donors. <i>Tetrahedron Letters</i> , 2003, 44, 9051-9054.	0.7	39
52	Analytical Techniques for Small Molecule Solid Phase Synthesis. <i>Current Medicinal Chemistry</i> , 2002, 9, 2103-2127.	1.2	18
53	Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 1399-1404.	1.0	30
54	Dihydropyranocarboxamides Related to Zanamivir: A New Series of Inhibitors of Influenza Virus Sialidases. 1. Discovery, Synthesis, Biological Activity, and Structure-Activity Relationships of 4-Guanidino- and 4-Amino-4H-pyran-6-carboxamides. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 787-797.	2.9	324

#	ARTICLE	IF	CITATIONS
55	Novel inhibitors of influenza sialidases related to GG167 structure-activity, crystallographic and Molecular dynamics studies with 4H-pyran-2-carboxylic acid 6-carboxamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1996, 6, 2931-2936.	1.0	58